<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li class="active"><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div>
					  </div>
					</nav>
					</div>
				</div>

			</div>

		</div>
	</header>



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>Toxicities</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section><!-- Fin de Banner Section -->




	<section class="franja">
	 <div class="overlay_franja">
		 <div class="container">
			 <div class="row">
				 <div class="col-md-12 col-sm-12 col-xs-12">
					 <div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
						 <h2>3<span class="negrita">.3</span> RENAL TOXICITY</h2>
						 <br/> <img src="images/ORGANOkidneySM.png" alt="" height="40px"/>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
 </section>
 <section class="texto">
	 <div class="container">
		 <div class="row">
			 <div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				 <p></p>
			 </div>
		 </div>
	 </div>
 </section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CLINICAL CASE</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Summary: 69 years old, melanoma on the first toe of the left foot. Surgical intervention on 13/07/17 with amputation, selective biopsy of the sentinel node (SBSN) negative, pT4b Stage IIC.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Recurrence in the form of subcutaneous, pulmonary, hepatic, and bony M1 melanomas. WT, LDH normal. </p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Pembrolizumab started on 09/11/18</p>
							<br/><br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/>
							<p><span class="negrita">&nbsp;7 months after starting Ppembrolizumab:</span></p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Asymptomatic patient</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Increased creatinine (clearance of 35 ml/min)</p>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="tabla">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

							<h2>Renal toxicity to immunotherapy? </h2>
							<br/> <br/>
							<p>Initial studies found a low incidence of renal toxicity associated with inhibitors at checkpoints (2-3%), but more recent data suggest a higher rate of around 13-29% (Cortazar, Kidney Int 2016, Mason JCO 2016, Hirsch J Am Soc Nephrol 2016).</p>
							<br/>
							<p>The most commonly reported renal toxicities were renal failure and hyponatraemia.</p>
							<br/>
							<p>Acute interstitial nephritis is the most common finding detected in biopsies.</p>
							<br/>
							<p>Cortazar and colleagues analysed data from phase 2 and 3 studies with patients who had acute renal failure and found an overall incidence of 2.2% among 3,695 patients, with severity in 0.6%.</p>
							<br/>
							<p>The incidence in patients treated with the combination of an anti-CTLA4 and an anti-PD1 (4.9%) was higher than in patients receiving monotherapy with either of them (1.4-2%). However, several analyses were later reported in which this incidence is greater.</p>
							<br/>
							<p>Another issue that also needs to be evaluated in prospective studies is the combination of chemotherapy with immunotherapy, as it seems that the renal toxicity appears in relation to either of the two agents in monotherapy and may alter the filtration of certain agents.</p>
							<br/>
							<p>The most frequent clinical manifestations of this renal toxicity are the increase in creatinine and pyuria, although there may also be haematuria, eosinophilia and worsening of arterial hypertension. Nephrotic syndrome is an rare finding that appears with the anti-CTLA4.</p>
							<br/>

						</div>
					</div>
				</div>
			</div>
		</div>
	</section>


	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
				<div class="main_counter_content text-center">
				<div class="col-md-12 col-sm-12 col-xs-12">


					<div class="marcoOSCURO wow fadeIn">

					<form>
					<br/> <br/> <br/>
					<h2>In the event of renal toxicity to Pembrolizumab, which approach seems to be the most appropriate?</h2>
					<br/> <br/> <br/> <br/>
					<label class="container">I would stop Pembrolizumab and perform tests.
						<input type="radio" name="pregunta1" id="p1">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would initiate corticosteroid therapy without stopping the Pembrolizumab and perform tests.
						<input type="radio" name="pregunta1" id="p2">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">I would continue the Pembrolizumab and monitor renal function.
						<input type="radio" name="pregunta1" id="p3">
						<span class="checkmark"></span>
					</label>
					<br/>
					<label class="container">It would rule out other causes of impaired renal function and would strictly monitor it without stopping the Pembrolizumab.
						<input type="radio" name="pregunta1" id="p3">
						<span class="checkmark"></span>
					</label>
					</form>



					<div class="pregunta wow fadeIn" data-wow-duration="1s">
						<a href="#"><img onclick="resultado();return false;" src="images/profesora.png" alt="" height="90px"/></a>
					</div>


						<div id="flotante" style="display:none;">


							<br/><br/><h2>Correct!</h2>
							<br/>
							<h2>The correct therapeutic decision would be<span class="negrita">:</span></h2>
							<br/> <br/>
							<p><span class="negrita">•</span> We performed a renal ultrasound, which was normal,</p>
							<br/><p><span class="negrita">•</span> We administered intravenous hydration and insisted on water intake</p>
							<br/><p><span class="negrita">•</span> We withdrew ACE inhibitors</p>
							<br/><p><span class="negrita">•</span> We stopped Pembrolizumab</p>


							<br/>
							<div class="separator"></div>

							<p>If acute renal failure is present in a patient receiving immunotherapy, we must always consider this possibility, but we should not forget that we must make a differential diagnosis with other entities.</p>



						</div>
						<div id="flotanteIncorrecto" style="display:none;">
							<br/><br/>
							<h2>This is not correct. Try again :)</h2>

						</div>


					</div>



			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>How do we define renal toxicity?</h2>
					<br/>
					<p>The grades of renal toxicity are defined according to the <span class="cursiva">Common Terminology Criteria for Adverse Events</span> (CTCAE), <span class="cursiva">Version 4.0</span> (CTCAE v4)</p>
					<br/>
					<table class="vikhi-tabla">
					<tr>
						<td><p>GRADE 1</p></td>
						<td><p>Mild symptoms</p><p>Creatinine above the upper limit of normal, but &lt;1.5 times this value</p></td>
					</tr>
					<tr>
						<td width="15%"><p>GRADE 2</p></td>
						<td><p>Moderate symptoms</p><p>Creatinine 1.5-6 times the upper limit of normal</p></td>
					</tr>
					<tr>
						<td width="15%"><p>GRADE 3</p></td>
						<td><p>Serious symptoms but no immediate risk to life</p><p>Creatinine 1.5-6 times the upper limit of normal</p></td>
					</tr>
					<tr>
						<td width="15%"><p>GRADE 4</p></td>
						<td><p>Serious symptoms with life-threatening symptoms requiring urgent intervention</p><p>Creatinine &gt; 6 times the upper limit of normal</p></td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>



	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

					<h2>Management of renal toxicity</h2>
					<br/>
					<p>Management of renal toxicity, due to immunotherapy will depend on its level of severity (<span class="cursiva">Wanchoo, Am J Nephrol 2017, Champiat Ann Oncol 2016, Kumar Frontiers in Pharmacology 2017, Bristol-Myers REMS 2012, Haanen, Ann Oncol. 2017; Thompson. J Natl Compr Canc Netw. 2018; Brahmer. J Clin Oncol. 2018</span>).</p>
					<br/>
					<p>The following table summarises its management:</p>
					<br/>
					<table class="vikhi-tabla">
					<tr>
						<th><p>GRADE</p></th>
						<th><p>Management</p></th>
						<th><p>Follow-up</p></th>
					</tr>
					<tr>
						<td width="5%"><p>1</p></td>
						<td width="47%"><p><span class="negrita">•</span> Support treatment</p><p><span class="negrita">•</span> Continue treatment and monitor renal function and water-electrolyte balance</p></td>
						<td width="48%"><p><span class="negrita">•</span> If renal function worsens, treat according to the corresponding degree</p></td>
					</tr>
					<tr>
						<td width="5%"><p>2–3</p></td>
						<td width="47%"><p><span class="negrita">•</span> Do not administer immunotherapy</p><p><span class="negrita">•</span> Oral prednisone 0.5-1 mg/kg/day or equivalent</p><p><span class="negrita">•</span> Monitoring of renal function and water-electrolyte balance every 2-3 days</p><p><span class="negrita">•</span> Consider renal biopsy</p></td>
						<td width="48%"><p><span class="negrita">•</span> If the symptoms are resolved and the toxicity decreases to &lt;GRADE 1, restart immunotherapy at the next dose</p><p><span class="negrita">•</span> Descending corticosteroid regimen for at least one month with weekly monitoring of renal function</p><p><span class="negrita">•</span> If there is no response in 3 days, increase prednisone to 2 mg/kg/day and discontinue immunotherapy permanently. If it persists for 7 days, treat as GRADE 4</p></td>
					</tr>
					<tr>
						<td width="5%"><p>4</p></td>
						<td width="47%"><p><span class="negrita">•</span> Discontinue immunotherapy permanently</p><p><span class="negrita">•</span> Oral prednisone 1-2 mg/kg/day or equivalent</p><p><span class="negrita">•</span> Monitoring of renal function and water-electrolyte balance</p><p><span class="negrita">•</span> Consult Nephrology</p>
						<p><span class="negrita">•</span> Consider ultrasound and/or biopsy</p></td>
						<td width="48%"><p><span class="negrita">•</span> After the symptoms have disappeared and the impaired renal function has been resolved, perform a descending corticosteroid regimen for at least 1 month with weekly monitoring of renal function</p></td>
					</tr>
					</table>
				</div>
			</div>
		</div>
	</section>
	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">
							<h2>Therapeutic decision for this patient <span class="negrita">:</span></h2>
							<br/>
							<p><span class="negrita">•</span> Due to the persistence of the impaired renal function, a renal biopsy was performed. Histology of tubulointerstitial nephritis was observed, attributable to Pembrolizumab.</p>
							<p><span class="negrita">•</span> We started prednisone, confirming one with slow but progressive improvement until it stabilised at 1.7 times the upper limit of normal. A descending regimen of corticosteroid therapy was given until its withdrawal 2 months after it was started.</p>
							<p><span class="negrita">•</span> Pembrolizumab was discontinued permanently.</p>
							<p><span class="negrita">•</span> 4 months after the last administration, the patient continues to have a partial response.</p>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>





	<section>
	 <div class="container">
		 <div class="row">

			 <div class="wedo_content_area">

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad01.html"><h4 class="gris">3.1 GASTROINTESTINAL TOX.</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad02.html"><h4 class="gris">3.2 PULMONARY TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad03.html"><h4 class="gris">3.3 RENAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad04.html"><h4>3<span class="turquesa">.4</span> LIVER TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad05.html"><h4>3<span class="turquesa">.5</span> ENDOCRINE TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad06.html"><h4>3<span class="turquesa">.6</span> CUTANEOUS TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad07.html"><h4>3<span class="turquesa">.7</span> NEUROLOGICAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad08.html"><h4>3<span class="turquesa">.8</span> OTHER TOXICITIES</h4></a>
						 </div>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>

	<script type="text/javascript" src="js/test.js"></script>




	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
